EMEA-001806-PIP04-19

Table of contents

Key facts

Invented name
Kyprolis
Active substance
carfilzomib
Therapeutic area
  • Haematology-Hemostaseology
  • Oncology
Decision number
P/0016/2021
PIP number
EMEA-001806-PIP04-19
Pharmaceutical form(s)
Powder for solution for infusion
Condition(s) / indication(s)
Treatment of acute lymphoblastic leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries
Amgen Europe BV

E-mail: medinfointernational@amgen.com
Tel. +44 (0)1223 420305

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating